Company
Immune-Onc
Immune-Onc is a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells
Also known as IMMUNE-ONC THERAPEUTICS, INC.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- IMMUNE-ONC THERAPEUTICS, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
We believe myeloid cell surface proteins represent the next wave of therapeutic targets in immunology and oncology. In collaboration with scientists, our research team is among the first in the world to validate these cell surface molecules as targets for novel therapies that have the potential to transform current treatment approaches for blood cancers, solid tumors as well as autoimmune and inflammatory diseases.
Funding snapshot
- Total raised
- $7MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $7M2016-07-01
Funding rounds
- Round, 2016
- $7M2016-07-01, SEC form D sold, 14 investors
About the company
- Status notes
- private, clinical-stage biopharmaceutical company developing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors
Loading relationship preview